Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Broccoli, Alessandro"'
Autor:
Nicola Cascavilla, Cristina Tecchio, Carlo Visco, Annalisa Chiappella, Maria Christina Cox, Roberto Marasca, Rossella Paolini, Beatrice Casadei, Gerardo Musuraca, Caterina Patti, Michelle Zancanella, Annarita Conconi, Maria Goldaniga, Angelo Fama, Dario Marino, Francesco Gaudio, Claudia Castellino, Alessandra Romano, Luigi Rigacci, Monica Tani, Monica Balzarotti, Federico Monaco, Alessandro Broccoli, Lisa Argnani, Liliana Devizzi, Pier Luigi Zinzani
Background Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma subtype, and approximately 50% of the patients are >60 years of age. Patients with relapsed/refractory (rr) disease have a poor prognosis with currently availabl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98a63b4ae6076e247de8356a0953673f
https://europepmc.org/articles/PMC6738312/
https://europepmc.org/articles/PMC6738312/
Autor:
Angelo Fama, Cinzia Pellegrini, Francesco Gaudio, Paolo Corradini, Monica Tani, Corrado Schiavotto, Donato Mannina, Stefano Volpetti, Amalia De Renzo, Stefano Molica, Alessandra Romano, Filippo Gherlinzoni, Alessandro Broccoli, Livio Trentin, Carmelo Carlo-Stella, Maurizio Bonfichi, Stefan Hohaus, Annalisa Arcari, Antonello Pinto, Patrizia Tosi, Pier Luigi Zinzani, Angelo Michele Carella, Guido Gini, Pellegrino Musto, Patrizio Mazza, Alice Di Rocco, Anna Marina Liberati, Anna Vanazzi, Caterina Patti, Benedetta Puccini, Giuseppe Gritti, Chiara Rusconi, Michele Merli, Vincenzo Pavone, Sergio Storti, Michele Spina, Angela Gravetti, Maria Goldaniga, Barbara Botto, Virginia Naso, Lisa Argnani, Vittorio Stefoni
Publikováno v:
Haematologica
Between November 2012 and July 2014, in accordance with national law 648/96, brentuximab vedotin was available in Italy for patients with relapsed systemic anaplastic large cell lymphoma outside a clinical trial context. A large Italian observational
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::061446c439e66716b026ce7b7fd7da8b
http://hdl.handle.net/11577/3250024
http://hdl.handle.net/11577/3250024
Autor:
Vittorio Stefoni, Vincenzo Pavone, Lisa Argnani, Alessandra Romano, Michele Merli, Pier Luigi Zinzani, Amalia De Renzo, Pellegrino Musto, Gian Matteo Rigolin, Maria Goldaniga, Luigi Rigacci, Monica Tani, Donato Mannina, Michele Spina, Angelo Michele Carella, Anna Marina Liberati, Armando Santoro, Alessandro Pulsoni, Patrizio Mazza, Corrado Schiavotto, Livio Trentin, Chiara Rusconi, Anna Vanazzi, Caterina Patti, Stefan Hoaus, Stefano Molica, Stefano Volpetti, Guido Gini, Maurizio Bonfichi, Maria Paola Bianchi, Paolo Corradini, Antonello Pinto, Alessandro Broccoli, Patrizia Tosi, Fioravante Ronconi, Filippo Gherlinzoni, Barbara Botto, Giuseppe Gritti, Daniele Vallisa, Cinzia Pellegrini, Francesco Gaudio, Angelo Fama
Publikováno v:
Oncotarget
A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin's lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94457167f00c920b149713c4f8512072
http://hdl.handle.net/11585/615058
http://hdl.handle.net/11585/615058
Autor:
Beatrice Casadei, Cinzia Pellegrini, Lorenzo Tonialini, Vittorio Stefoni, Pier Luigi Zinzani, Alice Morigi, Lisa Argnani, Letizia Gandolfi, Alessandro Broccoli
Background Brentuximab vedotin (BV) has shown high overall response rate in refractory/relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL) with reported long-term response duration in clinical trials, but few data are a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c3c1fd734f5dcb410eefee00fe3dde9
http://hdl.handle.net/11585/580324
http://hdl.handle.net/11585/580324